- This event has passed.
2022 Industry Update – Investment & Funding
April 13, 2022 @ 4:00 pm - 6:45 pm AEST
Event Navigation
(Please note – the In person allocation has been exhausted, you are welcome to attend online)
Sponsored by the State Government of Victoria, this BioForum: 2022 Industry Update – Investment and Funding, will provide an overview of some of the support and funding options available to help organisations within the biotech sector grow.
Participants will hear about investment options, incubators and accelerators from both private and government sources. Our expert speakers will examine how these resources can work together within the biotech ecosystem and how organisations can leverage this to benefit themselves and the biotech industry as a whole. We will be joined by the following speakers:
Grant Dooley, CEO, Breakthrough Victoria
Breakthrough Victoria is an independent investment management company established in 2021 to invest and manage the Victorian Government’s landmark $2 billion Breakthrough Victoria Fund. Grant will take us through Breakthrough Victoria’s investment plans for the health and life sciences sector.
Simon Wilkins, Head of Operations, CUREator
CUREator is a national biotechnology incubator run by Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund). It is a nationwide program offering grant funding for a select number of preclinical medical research and medical innovation projects, and clinical-stage novel therapeutics. Simon Wilkins will talk about the support that CUREator offers and the types of projects they fund.
Bronwyn Le Grice, CEO and Managing Director, ANDHealth
ANDHealth is Australia’s leading provider of accelerator, incubator and commercialisation programs for digital health technology companies. Bronwyn will present the programs and activities on offer from ANDHealth.
Lauren Kelly, Senior Director of our Targeted Translation Research Accelerator (TTRA) program at MTPConnect
MTPConnect is a not-for-profit organisation aiming to accelerate the rate of growth of the medtech, biotech and pharmaceutical sector in Australia. MTPConnect has two funding programs currently in market, TTRA and CTC-M. Lauren will speak to both programs along with the ongoing mentoring and commercialisation support provided by MTPConnect and specialist program partners.
Dr Kate Cornick, Chief Executive Officer, LaunchVic
LaunchVic is the state government agency responsible for growing and developing the Victorian startup ecosystem. Kate will be talking about some of the programs funded by LaunchVic in health and life sciences as well as presenting on LaunchVic’s investments into Victoria’s angel investor networks, and the $10m Alice Anderson Fund.
You can read more about our speakers below.
Who should attend?
CEOs, CFOs, R&D and Commercial Directors, Business Development Managers, Strategic Alliance and Partnership Managers, and anyone with an interest in understanding the array of support programs available to assist companies.
Event details
Date: Wednesday 13 April 2022
Time:
4:00pm – 5:45pm Presentations (in person and online)
5:45pm – 6:45pm Networking (in person only)
Format: In person and online via Zoom webinar
(Please note- the In person allocation has been exhausted, you are welcome to attend online)
Venue: Swinburne Studio, ACMI, Federation Square, Melbourne
In person registration: BioMelbourne Network Members: $75; Non Members: $150
Online registration: BioMelbourne Network Members: $20; Non Members: $40
Sponsored by the State Government of Victoria
Grant Dooley, CEO, Breakthrough Victoria
Mr Dooley commenced in the CEO role in November 2021, returning to his home town of Melbourne from Singapore where he formerly headed ARA Infrastructure, managing public and private investment across the Asia-Pacific region. He was previously an Executive Director and Head of Asia for Hastings Funds Management.
Prior to working in funds management, Mr Dooley had a distinguished career as a trade official for the Department of Foreign Affairs and Trade, including two years as the Australian Consul General in Guangzhou, southern China from 2010-12.
Prior to working in funds management, Mr Dooley had a distinguished career as a trade official for the Department of Foreign Affairs and Trade, including two years as the Australian Consul General in Guangzhou, southern China from 2010-12.
Simon Wilkins, Head of Operations, CUREator
Simon joined Brandon Capital in 2021.
Simon has 20+ years of experience in research commercialisation, business development and technology advisory, and has variously worked in biotech, pharma, strategy consulting to the innovation & technology sector, as well as in technology commercialisation and biomedical research. He brings a passion for innovation and community building, and a practical approach to solving the challenges around early-stage venture craft, industry collaboration and building a national biotech incubator.
Prior to joining Brandon, Simon worked as a Venture Creator within the New Ventures team as part of the University of Melbourne’s Research Innovation & Commercialisation (RIC) group. In 2016 he co-founded Translating Research at Melbourne (TRAM) as a cohort-based experiential program to develop the entrepreneurial capability and practical business skills of researchers at the University of Melbourne. Simon served for 5 years as TRAM founding Director, training over 300 researchers, attracting over $6M in investment and leading the establishment of 9 research-based startups.
Since 2020, Simon has held an Associate Professor (Adjunct) role with the Melbourne Business School, where he co-delivers the award-winning BioDesign Innovation course to Masters of Engineering and MBA students, building entrepreneurial capabilities by developing new medical technologies that solve unmet clinical needs.
Simon also holds commercial advisory roles at the intersection of digital technology and the health sector, as well as formal qualifications in biomedical research and business including his PhD (University of Queensland) in Developmental Genetics, a BScHons (Monash) in Physiology, a graduate certificate in applied finance (Kaplan Professional), and graduate Company Director’s course (AICD). From 2018-2021, Simon served on the Board of Directors for Knowledge Commercialisation Australasia (KCA), the peak body leading best practice in industry engagement, commercialisation and entrepreneurship for research organisations.
Simon has 20+ years of experience in research commercialisation, business development and technology advisory, and has variously worked in biotech, pharma, strategy consulting to the innovation & technology sector, as well as in technology commercialisation and biomedical research. He brings a passion for innovation and community building, and a practical approach to solving the challenges around early-stage venture craft, industry collaboration and building a national biotech incubator.
Prior to joining Brandon, Simon worked as a Venture Creator within the New Ventures team as part of the University of Melbourne’s Research Innovation & Commercialisation (RIC) group. In 2016 he co-founded Translating Research at Melbourne (TRAM) as a cohort-based experiential program to develop the entrepreneurial capability and practical business skills of researchers at the University of Melbourne. Simon served for 5 years as TRAM founding Director, training over 300 researchers, attracting over $6M in investment and leading the establishment of 9 research-based startups.
Since 2020, Simon has held an Associate Professor (Adjunct) role with the Melbourne Business School, where he co-delivers the award-winning BioDesign Innovation course to Masters of Engineering and MBA students, building entrepreneurial capabilities by developing new medical technologies that solve unmet clinical needs.
Simon also holds commercial advisory roles at the intersection of digital technology and the health sector, as well as formal qualifications in biomedical research and business including his PhD (University of Queensland) in Developmental Genetics, a BScHons (Monash) in Physiology, a graduate certificate in applied finance (Kaplan Professional), and graduate Company Director’s course (AICD). From 2018-2021, Simon served on the Board of Directors for Knowledge Commercialisation Australasia (KCA), the peak body leading best practice in industry engagement, commercialisation and entrepreneurship for research organisations.
Bronwyn Le Grice, CEO and Managing Director, ANDHealth
Bronwyn has over 18 years executive experience in the health technology sector spanning commercialisation, venture capital, capital raising and industry advocacy. Formerly an Investment Director with leading healthcare venture capital firm, BioScience Managers, between 2012 and 2017 she managed over $65M of private and public equity capital raisings and was actively involved in over $30M of portfolio investments.
In 2017, working with a consortium of industry partners, Bronwyn created ANDHealth, Australia’s only commercialisation organisation dedicated to digital health, with a specific focus on digital medicine and digital therapeutics. The novel ANDHealth+ program, piloted in 2018-2019, supported 10 companies to go on to raise over $47 million, create 296 jobs and impact more than 200,000 patients in under four years.
ANDHealth’s globally unique cooperative commercialisation model has led to significant growth within Australia’s nascent digital health sector and continues to be a driving force for the development of sovereign capability in evidence-based, regulated digital health technologies.
Bronwyn is a Non-Executive Director of Lumos Diagnostics Ltd (ASX.LDX) and holds various advisory roles including: the Australia New Zealand Leadership Forum Health Technologies Sector Group, Swinburne University’s Innovation Precinct Advisory Board, the RMIT University Health and BioMedical Sector Expert Research Advisory Group and the NSW Cyber Security Industry Standards Harmonisation Taskforce. In 2020 Bronwyn was awarded the Most Valuable Woman in Leadership Award by the BioMelbourne Network.
In 2017, working with a consortium of industry partners, Bronwyn created ANDHealth, Australia’s only commercialisation organisation dedicated to digital health, with a specific focus on digital medicine and digital therapeutics. The novel ANDHealth+ program, piloted in 2018-2019, supported 10 companies to go on to raise over $47 million, create 296 jobs and impact more than 200,000 patients in under four years.
ANDHealth’s globally unique cooperative commercialisation model has led to significant growth within Australia’s nascent digital health sector and continues to be a driving force for the development of sovereign capability in evidence-based, regulated digital health technologies.
Bronwyn is a Non-Executive Director of Lumos Diagnostics Ltd (ASX.LDX) and holds various advisory roles including: the Australia New Zealand Leadership Forum Health Technologies Sector Group, Swinburne University’s Innovation Precinct Advisory Board, the RMIT University Health and BioMedical Sector Expert Research Advisory Group and the NSW Cyber Security Industry Standards Harmonisation Taskforce. In 2020 Bronwyn was awarded the Most Valuable Woman in Leadership Award by the BioMelbourne Network.
Lauren Kelly, Senior Director, Targeted Translation Research Accelerator (TTRA), MTPConnect
Lauren Kelly is an experienced and dedicated research and alliance management professional, with over 10 years’ experience in developing, leading, and managing new initiatives, multidisciplinary teams, biobanks, pre-clinical and clinical R&D projects with local and global collaborators.
Since 2019, Lauren has managed nearly $70 million in MRFF funding across MTPConnect’s TTRA and BTB programs, which has supported 30 awardees from across Australia, and counting.
Before joining MTPConnect, Lauren managed industry-academic drug discovery and clinical development programs centring around obesity, diabetes and cardiovascular disease at Monash University, and biomarker discovery and diagnostic development for neurodegenerative diseases and psychoses at the Coorperative Research Centre for Mental Health. Lauren also developed and directed industry engagement initiatives for the Monash Biomedicine Discovery Institute. Lauren has a Bachelor of Science and Master of Business (Science and Technology) from Monash University, and a Graduate Diploma of Applied Corporate Governance.
Since 2019, Lauren has managed nearly $70 million in MRFF funding across MTPConnect’s TTRA and BTB programs, which has supported 30 awardees from across Australia, and counting.
Before joining MTPConnect, Lauren managed industry-academic drug discovery and clinical development programs centring around obesity, diabetes and cardiovascular disease at Monash University, and biomarker discovery and diagnostic development for neurodegenerative diseases and psychoses at the Coorperative Research Centre for Mental Health. Lauren also developed and directed industry engagement initiatives for the Monash Biomedicine Discovery Institute. Lauren has a Bachelor of Science and Master of Business (Science and Technology) from Monash University, and a Graduate Diploma of Applied Corporate Governance.
Dr Kate Cornick Chief Executive Officer, LaunchVic
Kate Cornick is the CEO of LaunchVic, the Victorian Government’s startup agency and has considerable experience in technological innovation across startups, academia, corporates and government.
An experienced non-executive director, Kate is currently a member of the Charles Sturt University Council and is a member of the auDA Board.
Prior to her current roles, Kate led the development of a human resources technology startup through a listing on the ASX. She held the position of Senior Telecommunications Adviser and Deputy Chief of Staff the Minister for Broadband, Communications and the Digital Economy and has also worked as a General Manager at NBN Co.
Kate Cornick undertook her PhD in optical telecommunications at the University of Melbourne.
An experienced non-executive director, Kate is currently a member of the Charles Sturt University Council and is a member of the auDA Board.
Prior to her current roles, Kate led the development of a human resources technology startup through a listing on the ASX. She held the position of Senior Telecommunications Adviser and Deputy Chief of Staff the Minister for Broadband, Communications and the Digital Economy and has also worked as a General Manager at NBN Co.
Kate Cornick undertook her PhD in optical telecommunications at the University of Melbourne.
OUR COVID-SAFE PRACTICES
In line with current COVID-19 restrictions in Victoria and ACMI’s COVID-Safe plan, in-person ticket allocation for this event is limited and adheres to the current Government restrictions applied to indoor event spaces.
To keep BioMelbourne Network events safe for our members and the greater Victorian community, this event will include measures such as physical distancing, QR code check-in and enhanced hygiene and sanitation processes. Further details will be made available to registered guests via our event webpage and final confirmation email.
Guests Attending In-Person
Each attendee is asked to do a symptom self-assessment prior to leaving home. We ask that you DO NOT attend this event in-person if you are feeling unwell, have any symptoms of COVID-19, are awaiting results of a COVID-19 test or are required to self-isolate or quarantine at the time of the event. Symptoms of COVID-19 include cough, fever, sore throat, fatigue and shortness of breath. If you cannot attend in-person for these reasons, you may receive a full refund or partial refund plus virtual ticket.
We ask that all in-person attendees act in a considerate and respectful manner towards our speakers, fellow guests, venue staff and BioMelbourne Network staff:
• On arrival, all guests must scan in via the QR codes displayed at the venue entrance.
• Maintain adequate physical distance between yourself and others, where possible.
• Refrain from unnecessary physical contact, such as hand shaking.
• Minimise movement by staying within your allocated spaces or seats, where practical.
• Observe all COVID-Safe signage and practices at the venue.
• Adhere to requirements for face covering, observe cough etiquette and personal hygiene measures.
To keep BioMelbourne Network events safe for our members and the greater Victorian community, this event will include measures such as physical distancing, QR code check-in and enhanced hygiene and sanitation processes. Further details will be made available to registered guests via our event webpage and final confirmation email.
Guests Attending In-Person
Each attendee is asked to do a symptom self-assessment prior to leaving home. We ask that you DO NOT attend this event in-person if you are feeling unwell, have any symptoms of COVID-19, are awaiting results of a COVID-19 test or are required to self-isolate or quarantine at the time of the event. Symptoms of COVID-19 include cough, fever, sore throat, fatigue and shortness of breath. If you cannot attend in-person for these reasons, you may receive a full refund or partial refund plus virtual ticket.
We ask that all in-person attendees act in a considerate and respectful manner towards our speakers, fellow guests, venue staff and BioMelbourne Network staff:
• On arrival, all guests must scan in via the QR codes displayed at the venue entrance.
• Maintain adequate physical distance between yourself and others, where possible.
• Refrain from unnecessary physical contact, such as hand shaking.
• Minimise movement by staying within your allocated spaces or seats, where practical.
• Observe all COVID-Safe signage and practices at the venue.
• Adhere to requirements for face covering, observe cough etiquette and personal hygiene measures.
Related Events
